» Articles » PMID: 21474797

Label-free Quantitative Proteomics Reveals Differentially Regulated Proteins Influencing Urolithiasis

Overview
Date 2011 Apr 9
PMID 21474797
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Urinary proteins have been implicated as inhibitors of kidney stone formation (urolithiasis). As a proximal fluid, prefiltered by the kidneys, urine is an attractive biofluid for proteomic analysis in urologic conditions. However, it is necessary to correct for variations in urinary concentration. In our study, individual urine samples were normalized for this variation by using a total protein to creatinine ratio. Pooled urine samples were compared in two independent experiments. Differences between the urinary proteome of stone formers and nonstone-forming controls were characterized and quantified using label-free nano-ultraperformance liquid chromatography high/low collision energy switching analysis. There were 1063 proteins identified, of which 367 were unique to the stone former groups, 408 proteins were unique to the control pools, and 288 proteins were identified for comparative quantification. Proteins found to be unique in stone-formers were involved in carbohydrate metabolism pathways and associated with disease states. Thirty-four proteins demonstrated a consistent >twofold change between stone formers and controls. For ceruloplasmin, one of the proteins was shown to be more than twofold up-regulated in the stone-former pools, this observation was validated in individuals by enzyme-linked immunosorbent assay. Moreover, in vitro crystallization assays demonstrated ceruloplasmin had a dose-dependent increase on calcium oxalate crystal formation. Taken together, these results may suggest a functional role for ceruloplasmin in urolithiasis.

Citing Articles

Self-control study of multi-omics in identification of microenvironment characteristics in calcium oxalate kidney stones.

Xu S, Liu Z, Zhang T, Li B, Cao Y, Wang X BMC Nephrol. 2025; 26(1):104.

PMID: 40016672 PMC: 11869433. DOI: 10.1186/s12882-025-04026-1.


Meta-data analysis of kidney stone disease highlights ATP1A1 involvement in renal crystal formation.

Li Y, Lu X, Yu Z, Wang H, Gao B Redox Biol. 2023; 61:102648.

PMID: 36871182 PMC: 10009205. DOI: 10.1016/j.redox.2023.102648.


Protein network analysis and functional enrichment via computational biotechnology unravel molecular and pathogenic mechanisms of kidney stone disease.

Peerapen P, Thongboonkerd V Biomed J. 2023; 46(2):100577.

PMID: 36642221 PMC: 10267970. DOI: 10.1016/j.bj.2023.01.001.


iTRAQ-Based Comparative Proteomics Analysis of Urolithiasis Rats Induced by Ethylene Glycol.

Cao Y, Duan B, Gao X, Wang E, Dong Z Biomed Res Int. 2020; 2020:6137947.

PMID: 32509863 PMC: 7246402. DOI: 10.1155/2020/6137947.


A Proteomic Network Approach across the Kidney Stone Disease Reveals Endoplasmic Reticulum Stress and Crystal-Cell Interaction in the Kidney.

Yang B, Lu X, Li Y, Li Y, Yu D, Zhang W Oxid Med Cell Longev. 2019; 2019:9307256.

PMID: 31772715 PMC: 6854948. DOI: 10.1155/2019/9307256.


References
1.
Kulaksizoglu S, Sofikerim M, Cevik C . Impact of various modifiers on calcium oxalate crystallization. Int J Urol. 2007; 14(3):214-8. DOI: 10.1111/j.1442-2042.2007.01688.x. View

2.
Mo L, Liaw L, Evan A, Sommer A, Lieske J, Wu X . Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. Am J Physiol Renal Physiol. 2007; 293(6):F1935-43. DOI: 10.1152/ajprenal.00383.2007. View

3.
Ginsberg J, Chang B, Matarese R, GARELLA S . Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med. 1983; 309(25):1543-6. DOI: 10.1056/NEJM198312223092503. View

4.
Kleinman J, Wesson J, Hughes J . Osteopontin and calcium stone formation. Nephron Physiol. 2004; 98(2):p43-7. DOI: 10.1159/000080263. View

5.
Ryall R . Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol. 1997; 15(3):155-64. DOI: 10.1007/BF02201852. View